How Has The Idiopathic Pulmonary Fibrosis Market Size Evolved In Recent Years?
The idiopathic pulmonary fibrosis market has seen considerable growth due to a variety of factors.
•The market size for idiopathic pulmonary fibrosis has seen robust growth in the last few years. The market is expected to expand from $4.15 billion in 2024 to $4.39 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.6%.
The substantial growth during the historical period can be credited to factors such as an rising elderly population, the scarcity of treatment options, increasing understanding of the disease, and advancements in healthcare infrastructure.
What Is The Projected Growth Of The Idiopathic Pulmonary Fibrosis Market?
The idiopathic pulmonary fibrosis market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for idiopathic pulmonary fibrosis is projected to experience substantial growth in the coming years, reaching a value of $5.74 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%.
This projected growth can be linked to advancements in research and development, the adoption of precision medicine, rising disease rates, advancements in biomarker development, as well as government initiatives and funding. The future trends identified include advancements in diagnostic methods, the development of targeted treatments, the utilization of telemedicine and remote monitoring, combination therapies, and progress in lung transplantation techniques.
What Are The Primary Growth Drivers In The Idiopathic Pulmonary Fibrosis Market?
The idiopathic pulmonary fibrosis market is foreseen to experience growth due to the rising incidence of fibrotic disease. Fibrotic diseases, or fibrosis, encompass a range of medical conditions marked by an overwhelming formation and buildup of fibrous connective tissue within various organs or tissues throughout the body. Drugs for idiopathic pulmonary fibrosis work to lessen lung fibrosis and inflammation by focusing on numerous signaling pathways involved in fibrosis. For example, the American Lung Association reported in December 2022 that approximately 207,000 individuals in the United States were affected, with around 58,000 new idiopathic pulmonary fibrosis diagnoses each year. This disease is typically more prevalent in men, largely affecting those above the age of 50. As a result, the idiopathic pulmonary fibrosis market is fuelled by the increased prevalence of fibrotic disease.
What Is The Segmentation Of The Global Idiopathic Pulmonary Fibrosis Market?
The idiopathic pulmonary fibrosis market covered in this report is segmented –
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users
Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies
Pre-Book The Idiopathic Pulmonary Fibrosis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Idiopathic Pulmonary Fibrosis Market Landscape?
The most common trend gaining traction in the idiopathic pulmonary fibrosis market is product innovation. Major players in the idiopathic pulmonary fibrosis market are concentrating their efforts on creating innovative products to consolidate their market position and gain a competitive edge. Take for example, Sandoz, a Switzerland-based manufacturer of generic and biosimilar medications, who in May 2022, launched a generic version of pirfenidone. This product, the first AB-rated equivalent of Genentech's Esbriet, is targeted at treating patients with idiopathic pulmonary fibrosis (IPF). This prescription medication, which is orally administered, is now available to patients via specialty pharmacies. Additionally, eligible patients may avail of a USD 0 co-pay program.
Who Are the Key Players in the Idiopathic Pulmonary Fibrosis Market?
Major companies operating in the idiopathic pulmonary fibrosis market include:
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Sanofi S.A.
• Gilead Sciences Inc.
• Toray Industries Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Sun Pharmaceutical Industries Limited
• Shionogi and Co. Ltd.
• Cipla Inc.
• Zydus Lifesciences Ltd.
• Chong Kun Dang Pharmaceutical Corp.
• Kyorin Pharmaceutical Co. Ltd.
• Galapagos NV
• Veracyte Inc.
• Genentech Inc.
• FibroGen Inc.
• GNI Group Ltd.
• Pliant Therapeutics Inc.
• Pulmatrix Inc.
• Galimedix Therapeutics Inc.
• Avalyn Pharma Inc.
• MediciNova Inc.
• Liminal BioSciences Inc.
• Beijing Continent Pharmaceuticals Company
• Galecto Inc.
What are the Regional Insights into the Idiopathic Pulmonary Fibrosis Market?
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
